Volume 6 Supplement 1

Fifth Dominique Dormont International Conference. Host-Pathogen Interactions in Chronic Infections

Open Access

Evolution of the biological follow-up of efficiency and tolerance of a once daily antiretroviral treatment with 3TC+DDI+EFV in children infected with HIV-1 (CLINICAL TRIAL ANRS 12 103)

  • Boubacar Nacro1,
  • Yaya Diasso2,
  • Emmanuelle Zoure1,
  • Potiendi Serge Diabouga3,
  • Philippe Van de Perre4,
  • Aly Drabo3,
  • Adama Ouiminga3,
  • François Rouet3,
  • Dramane Kania3,
  • Souleymane Yameogo5,
  • Alain Hien5,
  • Hervé Hien6 and
  • Philippe Msellati7
Retrovirology20096(Suppl 1):P12


Published: 22 July 2009


To study the evolution of biological parameters of efficiency and tolerance of the anti retroviral treatment (3TC, DDI, EFV) in child.


A total of 52 HIV1 infected children have been included in the study and have receiving a once daily dose of Lamivudine, Didanosine and Efavirenz. The follow up biological parameters have been collected quarterly in a period of one year.


The medium age was 6.83 years, with an age range of 2.5 to 14.5 years. The clinical stages at the enrolment were the following: 1 at stage N, 18 at stage A, 27 at stage B, 6 at stage C. At the biological level, the medium gain of CD4 in the children, after a period of one year of follow-up was of 14% (8.6% in inclusion). At the 12th month of follow-up, 51% of the patients had an undetectable viral load (<50 copies/mL) and 78% (<300 copies/mL). The mean values of the biologic parameters in blood such as platelets, ALAT, bilirubine, the blood sugar, cholesterol, the triglycerid and the creatinine were always in the norms. Despite a meaningful increase to M12, the mean rate of haemoglobin was always inferior to the norms (10.60 ± 1.01 to M12). Regarding the biological perturbations, grade III or IV, it has been observed an increase of the transamisases in 1% of the patients and mainly an elevation of the amylasemia in 3.9%, 2%, 13.7% and 10% of the children respectively on M3, M6, M9 and M12.


The biologic tolerance and the efficiency of the treatment are satisfactory. The rate of haemoglobin, the transaminases, and the amylasemia appear to be the determining criteria for the follow-up of the moderate toxicity of this short-term treatment.

Authors’ Affiliations

Pediatric Department CHUSS
Laboratories Department CHUSS
Immunology laboratories Centre Muraz
Bacteriology and Virology laboratories CHU Arnaud de Villeneuve
Pharmacy Department CHUSS
Epidemiology Department Centre Muraz
URM 145, IRD


© Nacro et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.